Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Canada
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4-piperidinecarboxylic Acid, 4-amino-1-((2r)-6-amino-2-(((2r)-2-(((2r)-2-(((2r)-2-amino-1-oxo-3-phenylpropyl)amino)-1-oxo-3-phenylpropyl)amino)-4-methyl-1-oxopentyl)amino)-1-oxohexyl)-
2. Korsuva
3. N-((2r)-1-(((2r)-1-(((2r)-6-amino-1-(4-amino-4-carboxy-1-piperidinyl)-1-oxo-2-hexanyl)amino)-4-methyl-1-oxo-2-pentanyl)amino)-1-oxo-3-phenyl-2-propanyl)-d-phenylalaninamide
1. 1024828-77-0
2. Cr845
3. Difelikefalin [inn]
4. Mr13a9
5. Cr-845
6. Korsuva
7. Fe202845
8. Na1u919mro
9. Fe-202845
10. Mr-13a9
11. 1024828-77-0 (free Base)
12. 1-(d-phenylalanyl-d-phenylalanyl-d-leucyl-d-lysyl)-4-aminopiperidine-4-carboxylic Acid
13. 4-piperidinecarboxylic Acid, N1-(d-phenylalanyl-d-phenylalanyl-d-leucyl-d-lysyl)-4-amino-
14. 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic Acid
15. Difelikefalin Acetate [jan]
16. Unii-na1u919mro
17. Kapruvia
18. Difelikefalin Tfa
19. Cr 845
20. Difelikefalin (cr845)
21. Difelikefalin (usan/inn)
22. Difelikefalin [usan:inn]
23. Difelikefalin [usan]
24. Seq Id No: 2
25. Difelikefalin [who-dd]
26. Gtpl9044
27. Chembl3989915
28. Schembl10316464
29. Bdbm235785
30. Dtxsid401032896
31. Bcp24752
32. Ex-a5855
33. At30197
34. Db11938
35. Bd177570
36. Hy-17609
37. Cr-845; Fe-202845
38. Cs-0014687
39. D11111
40. Us9359399, 2
41. Q21098992
42. D-phe-d-phe-d-leu-d-lys-[gamma-(4-n-piperidinyl)amino Carboxylic Acid]
43. 4-piperidinecarboylic Acid, 4-amino-1-(d-phenylalanyl-d-phenylalanyl-d-leucyl-d-lysyl)-
44. 4-amino-1-(d-phenylalanyl-d-phenylalanyl-d-leucyl-d-lysyl)piperidine-4-carboxylic Acid
45. 4-piperidinecarboxylic Acid, 4-amino-1-((2r)-6-amino-2-(((2r)-2-(((2r)-2-(((2r)-2-amino-1-oxo-3-phenylpropyl)amino)-1-oxo-3-phenylpropyl)amino)-4-methyl-1-oxopentyl)amino)-1-oxohexyl)-
46. N-((2r)-1-(((2r)-1-(((2r)-6-amino-1-(4-amino-4-carboxy-1-piperidinyl)-1-oxo-2-hexanyl)amino)-4-methyl-1-oxo-2-pentanyl)amino)-1-oxo-3-phenyl-2-propanyl)-d-phenylalaninamide
Molecular Weight | 679.8 g/mol |
---|---|
Molecular Formula | C36H53N7O6 |
XLogP3 | -0.6 |
Hydrogen Bond Donor Count | 7 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 18 |
Exact Mass | 679.40573244 g/mol |
Monoisotopic Mass | 679.40573244 g/mol |
Topological Polar Surface Area | 223 Ų |
Heavy Atom Count | 49 |
Formal Charge | 0 |
Complexity | 1080 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Difelikefalin is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP; uremic pruritus) in adults undergoing hemodialysis.
FDA Label
Kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5. 1).
Difelikefalin is administered to patients undergoing hemodialysis for chronic kidney disease (CKD) to prevent and treat the pruritus often associated with CKD. It is administered via bolus intravenous injection at the end of each hemodialysis treatment. As it works on opioid receptors, difelikefalin can cause dizziness, somnolence, and other CNS depressant effects that may impair mental or physical abilities - as such, patients should be advised to avoid operating dangerous machinery until the effect of difelikefalin on that patient is known.
V03AX
V - Various
V03 - All other therapeutic products
V03A - All other therapeutic products
V03AX - Other therapeutic products
V03AX04 - Difelikefalin
Absorption
Difelikefalin is administered via bolus intravenous injection with each hemodialysis treatment - for this reason, each dose is effectively 100% bioavailable.
Route of Elimination
Following intravenous difelikefalin administration to hemodialysis patients, approximately 11% of the dose was excreted in the urine, 59% in the feces, and 20% in the dialysate.
Volume of Distribution
The mean volume of distribution of difelikefalin is approximately 238 mL/kg.
Clearance
One cycle of hemodialysis reduces difelikefalin plasma concentrations by 70-80% and no detectable drug remains after two cycles.
Difelikefalin is not metabolized to any appreciable extent and is not a substrate for cytochrome P450 enzymes.
The half-life of difelikefalin in hemodialysis patients prior to dialysis ranges between 23 and 31 hours.
Difelikefalin is a synthetic peptide and agonist of kappa opioid receptors (KORs), which have long been known to be involved with the itching sensation (in addition to playing some role in addiction). Endogenous KOR agonists - called dynorphins - have a neuroinhibitory effect on the itching sensation at the spinal cord level and mouse models have shown KOR agonist antipruritic activity when used to treat itching induced by different pruritogens. Although the specifics of the mechanism have yet to be elucidated, the administration of KOR agonists, like difelikefalin, in patients with uremic pruritus has proven an effective means to suppress scratching and improve their quality of life.
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38511
Submission : 2023-06-19
Status : Active
Type : II
NDC Package Code : 52076-6273
Start Marketing Date : 2021-12-14
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38645
Submission : 2023-08-02
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37712
Submission : 2023-01-25
Status : Active
Type : II
Registration Number : 304MF10128
Registrant's Address : 7 rue de Boulogne 67100 Strasbourg, France
Initial Date of Registration : 2022-09-08
Latest Date of Registration : --
NDC Package Code : 59162-0002
Start Marketing Date : 2021-01-08
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38511
Submission : 2023-06-19
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38645
Submission : 2023-08-02
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37712
Submission : 2023-01-25
Status : Active
Type : II
Registration Number : 304MF10128
Registrant's Address : 7 rue de Boulogne 67100 Strasbourg, France
Initial Date of Registration : 2022-09-08
Latest Date of Registration : 2023-07-19
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
NDC Package Code : 52076-6273
Start Marketing Date : 2021-12-14
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59162-0002
Start Marketing Date : 2021-01-08
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
About the Company : Established in 1984, Neuland Laboratories Limited is a publicly listed company headquartered in Hyderabad, India. The company provides solutions across the entire spectrum of the p...
About the Company : Aspen API is the cooperative entity formed by Aspen Oss in the Netherlands and Fine Chemicals Corporation in South Africa. With quality, compliance, and teamwork at its core, Aspen...
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
About the Company : Chunghwa Chemical Synthesis & Biotech Co. Ltd. (CCSB) offers global customers cost-effective APIs with speed, supported by our well-trained staff. As the first company in Southeast...
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
About the Company : Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically...
About the Company : ALP Pharm began to manufacture some APIs in the partner's facilities in 2007. Some of our APIs have been approved by EDQM and US FDA. Our professional regulatory compliance experts...
Details:
Korsuva (difelikefalin) is a kappa opioid receptor agonists. Its oral formulation is under development for the treatment of moderate-to-severe pruritus in adult patients with notalgia paresthetica.
Lead Product(s): Difelikefalin
Therapeutic Area: Dermatology Brand Name: Korsuva
Study Phase: Phase II/ Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2024
Lead Product(s) : Difelikefalin
Therapeutic Area : Dermatology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cara Therapeutics: Outcome of KOURAGE-1 Study on Oral Difelikefalin in Notalgia
Details : Korsuva (difelikefalin) is a kappa opioid receptor agonists. Its oral formulation is under development for the treatment of moderate-to-severe pruritus in adult patients with notalgia paresthetica.
Brand Name : Korsuva
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 12, 2024
Details:
CR845 (difelikefalin) is a kappa opioid receptor agonists. Its oral formulation is under clinical development for the treatment of moderate-to-severe pruritus in patients with Atopic Dermatitis.
Lead Product(s): Difelikefalin
Therapeutic Area: Dermatology Brand Name: CR845
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Lead Product(s) : Difelikefalin
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CR845 (difelikefalin) is a kappa opioid receptor agonists. Its oral formulation is under clinical development for the treatment of moderate-to-severe pruritus in patients with Atopic Dermatitis.
Brand Name : CR845
Molecule Type : Peptide
Upfront Cash : Not Applicable
December 18, 2023
Details:
Cara intends to use the proceeds from the agreement to support the ongoing clinical development of its oral CR845 (difelikefalin) pipeline, including late-stage programs for pruritus associated with atopic dermatitis, advanced chronic kidney disease, and notalgia paresthetica.
Lead Product(s): Difelikefalin
Therapeutic Area: Dermatology Brand Name: CR845
Study Phase: Phase IIProduct Type: Peptide
Sponsor: HealthCare Royalty
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Financing November 02, 2023
Lead Product(s) : Difelikefalin
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : HealthCare Royalty
Deal Size : $40.0 million
Deal Type : Financing
Details : Cara intends to use the proceeds from the agreement to support the ongoing clinical development of its oral CR845 (difelikefalin) pipeline, including late-stage programs for pruritus associated with atopic dermatitis, advanced chronic kidney disease, and...
Brand Name : CR845
Molecule Type : Peptide
Upfront Cash : Undisclosed
November 02, 2023
Details:
Korsuva (difelikefalin) injection is a kappa opioid receptor agonist indicated for the treatment of moderate-to-severe pruritus in hemodialysis patients.
Lead Product(s): Difelikefalin
Therapeutic Area: Dermatology Brand Name: Korsuva
Study Phase: ApprovedProduct Type: Peptide
Sponsor: Maruishi Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Lead Product(s) : Difelikefalin
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Maruishi Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment ...
Details : Korsuva (difelikefalin) injection is a kappa opioid receptor agonist indicated for the treatment of moderate-to-severe pruritus in hemodialysis patients.
Brand Name : Korsuva
Molecule Type : Peptide
Upfront Cash : Not Applicable
September 25, 2023
Details:
Kapruvia® (difelikefalin) is a selective kappa opioid receptor agonist with low central nervous system penetration. It is recommended by NICE for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.
Lead Product(s): Difelikefalin
Therapeutic Area: Nephrology Brand Name: Kapruvia
Study Phase: ApprovedProduct Type: Peptide
Sponsor: CARA Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2023
Lead Product(s) : Difelikefalin
Therapeutic Area : Nephrology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : CARA Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Kapruvia® (difelikefalin) Recommended By England's NICE For the Treatment of Adults with Moderate...
Details : Kapruvia® (difelikefalin) is a selective kappa opioid receptor agonist with low central nervous system penetration. It is recommended by NICE for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.
Brand Name : Kapruvia
Molecule Type : Peptide
Upfront Cash : Not Applicable
May 18, 2023
Details:
CR845 (difelikefalin) is an oral agonist of kappa opioid receptors (KORs) It is being developed for the treatment of pruritus secondary to chronic kidney disease and notalgia paresthetica.
Lead Product(s): Difelikefalin
Therapeutic Area: Neurology Brand Name: CR845
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Lead Product(s) : Difelikefalin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CR845 (difelikefalin) is an oral agonist of kappa opioid receptors (KORs) It is being developed for the treatment of pruritus secondary to chronic kidney disease and notalgia paresthetica.
Brand Name : CR845
Molecule Type : Peptide
Upfront Cash : Not Applicable
February 08, 2023
Details:
The milestone payment is related to continued clinical progress of Oral KORSUVA (difelikefalin), which is currently the subject of four separate clinical programs for pruritus in patients with hepatic impairment due to primary biliary cholangitis.
Lead Product(s): Difelikefalin
Therapeutic Area: Dermatology Brand Name: Korsuva
Study Phase: Phase IIProduct Type: Peptide
Sponsor: CARA Therapeutics
Deal Size: $46.0 million Upfront Cash: $8.0 million
Deal Type: Licensing Agreement October 10, 2022
Lead Product(s) : Difelikefalin
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : CARA Therapeutics
Deal Size : $46.0 million
Deal Type : Licensing Agreement
Details : The milestone payment is related to continued clinical progress of Oral KORSUVA (difelikefalin), which is currently the subject of four separate clinical programs for pruritus in patients with hepatic impairment due to primary biliary cholangitis.
Brand Name : Korsuva
Molecule Type : Peptide
Upfront Cash : $8.0 million
October 10, 2022
Details:
The primary efficacy endpoint of change from baseline in the weekly mean of the daily 24-hour Worst Itch-Numeric Rating Scale (WI-NRS) score at Week 8 was achieved for Korsuva (difelikefalin) vs. -2.4 placebo, p=0.001.
Lead Product(s): Difelikefalin
Therapeutic Area: Neurology Brand Name: Korsuva
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Lead Product(s) : Difelikefalin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The primary efficacy endpoint of change from baseline in the weekly mean of the daily 24-hour Worst Itch-Numeric Rating Scale (WI-NRS) score at Week 8 was achieved for Korsuva (difelikefalin) vs. -2.4 placebo, p=0.001.
Brand Name : Korsuva
Molecule Type : Peptide
Upfront Cash : Not Applicable
September 08, 2022
Details:
KOMFORT Phase 2 clinical trial evaluating oral Korsuva (difelikefalin) for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica will be presented during a late-breaking news session.
Lead Product(s): Difelikefalin
Therapeutic Area: Dermatology Brand Name: Korsuva
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Lead Product(s) : Difelikefalin
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KOMFORT Phase 2 clinical trial evaluating oral Korsuva (difelikefalin) for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica will be presented during a late-breaking news session.
Brand Name : Korsuva
Molecule Type : Peptide
Upfront Cash : Not Applicable
August 22, 2022
Details:
Kapruvia® (difelikefalin) will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients.
Lead Product(s): Difelikefalin
Therapeutic Area: Dermatology Brand Name: Kapruvia
Study Phase: ApprovedProduct Type: Peptide
Sponsor: CARA Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2022
Lead Product(s) : Difelikefalin
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : CARA Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Kapruvia® Approved in Switzerland With Additional Regulatory Decisions Expected in H2 2022
Details : Kapruvia® (difelikefalin) will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients.
Brand Name : Kapruvia
Molecule Type : Peptide
Upfront Cash : Not Applicable
August 19, 2022
Regulatory Info : RX
Registration Country : USA
Brand Name : KORSUVA
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)
Packaging :
Approval Date : 2021-08-23
Application Number : 214916
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : Switzerland
Brand Name : Kapruvia
Dosage Form : Inj L?s
Dosage Strength : 0.05mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Australia
Brand Name : Korsuva
Dosage Form :
Dosage Strength :
Packaging : 12
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Korsuva
Dosage Form :
Dosage Strength :
Packaging : 12
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Korsuva
Dosage Form :
Dosage Strength :
Packaging : 12
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Korsuva
Dosage Form :
Dosage Strength :
Packaging : 12
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
RLD : Yes
TE Code :
Brand Name : KORSUVA
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)
Approval Date : 2021-08-23
Application Number : 214916
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Regulatory Info :
Registration Country : Switzerland
Brand Name : Kapruvia
Dosage Form : Inj L?s
Dosage Strength : 0.05mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Australia
Brand Name : Korsuva
Dosage Form :
Dosage Strength :
Packaging : 12
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Korsuva
Dosage Form :
Dosage Strength :
Packaging : 12
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Korsuva
Dosage Form :
Dosage Strength :
Packaging : 12
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Korsuva
Dosage Form :
Dosage Strength :
Packaging : 12
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2027-11-12
US Patent Number : 10138270
Drug Substance Claim :
Drug Product Claim :
Application Number : 214916
Patent Use Code : U-3204
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-11-12
Patent Expiration Date : 2027-11-12
US Patent Number : 8217007
Drug Substance Claim :
Drug Product Claim :
Application Number : 214916
Patent Use Code : U-3204
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-11-12
Patent Expiration Date : 2027-11-12
US Patent Number : 8236766
Drug Substance Claim :
Drug Product Claim :
Application Number : 214916
Patent Use Code : U-3204
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-11-12
Patent Expiration Date : 2027-11-12
US Patent Number : 8486894
Drug Substance Claim :
Drug Product Claim :
Application Number : 214916
Patent Use Code : U-3204
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-11-12
Patent Expiration Date : 2027-11-12
US Patent Number : 8536131
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 214916
Patent Use Code : U-3204
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-11-12
Patent Expiration Date : 2027-11-12
US Patent Number : 9334305
Drug Substance Claim :
Drug Product Claim :
Application Number : 214916
Patent Use Code : U-3204
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-11-12
Patent Expiration Date : 2027-11-12
US Patent Number : 10793596
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 214916
Patent Use Code : U-3204
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-11-12
Patent Expiration Date : 2027-11-12
US Patent Number : 9359399
Drug Substance Claim :
Drug Product Claim :
Application Number : 214916
Patent Use Code : U-3204
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-11-12
Patent Expiration Date : 2027-11-12
US Patent Number : 7713937
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 214916
Patent Use Code : U-3204
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-11-12
Patent Expiration Date : 2027-11-12
US Patent Number : 10017536
Drug Substance Claim : Y
Drug Product Claim :
Application Number : 214916
Patent Use Code : U-3204
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-11-12
Exclusivity Code : NCE
Exclusivity Expiration Date : 2026-08-23
Application Number : 214916
Product Number : 1
Exclusivity Details :
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?